Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
55.11
+2.34 (4.43%)
At close: Jun 26, 2026, 4:00 PM EDT
55.34
+0.23 (0.42%)
After-hours: Jun 26, 2026, 7:40 PM EDT
Spruce Biosciences Employees
Spruce Biosciences had 14 employees as of March 31, 2026. The number of employees increased by 6 or 75.00% since the number was last reported on December 31, 2025.
Employees
14
Change
6
Growth
75.00%
Revenue / Employee
n/a
Profits / Employee
-$2,656,500
Market Cap
151.68M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| ProQR Therapeutics | 187 |
| Humacyte | 184 |
| Molecular Partners AG | 134 |
| Alpha Cognition | 71 |
| Tenaya Therapeutics | 70 |
| Connect Biopharma Holdings | 64 |
| Pyxis Oncology | 56 |
| Corbus Pharmaceuticals Holdings | 36 |
SPRB News
- 6 days ago - Spruce Biosciences appoints Agnieszka Jurecka as VP, medical affairs - TheFly
- 6 days ago - Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs - Business Wire
- 12 days ago - Spruce Biosciences initiated with a Buy at Guggenheim - TheFly
- 13 days ago - Spruce Biosciences names Eric Jordan VP, marketing, Tina Gullotta VP, finance - TheFly
- 13 days ago - Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller - Business Wire
- 19 days ago - Spruce Biosciences initiated with a Buy at JonesResearch - TheFly
- 19 days ago - Spruce says long-term TA-ERT data presented at MPS Symposium - TheFly
- 19 days ago - Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium - Business Wire